Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Sep 27, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Testing New Neoadjuvant Combos in NSCLC

    Cancer Discovery
    |April 12, 2022
    PubMed
    Summary

    In early-stage lung cancer, combining treatments with durvalumab may improve neoadjuvant efficacy. The NeoCOAST trial explored these strategies for operable non-small cell lung cancer patients.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Thoracic Surgery

    Background:

    • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
    • Neoadjuvant therapy aims to reduce tumor burden before surgery.
    • PD-L1 inhibitors have shown promise in various cancer types.

    Purpose of the Study:

    • To evaluate the neoadjuvant efficacy of durvalumab in combination with other agents.
    • To assess the safety and tolerability of neoadjuvant combination strategies in early-stage NSCLC.

    Main Methods:

    • NeoCOAST trial: a phase II clinical study.
    • Inclusion of patients with early-stage operable non-small cell lung cancer.
    • Administration of durvalumab in combination with chemotherapy or other targeted agents.

    More Related Videos

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    10.6K
    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
    06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.1K

    Related Experiment Videos

    Last Updated: Sep 27, 2025

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.3K
    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    10.6K
    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
    06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.1K

    Main Results:

    • Combination strategies demonstrated potential to enhance neoadjuvant efficacy.
    • Durvalumab-based regimens showed promising results in the neoadjuvant setting.
    • Further analysis is ongoing to confirm the observed benefits.

    Conclusions:

    • Combination therapies including durvalumab may represent a promising approach for neoadjuvant treatment in early-stage NSCLC.
    • These findings warrant further investigation in larger clinical trials.
    • Optimizing neoadjuvant strategies can improve outcomes for operable lung cancer patients.